Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions

Fineline Cube May 22, 2026
Company Deals

Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform

Fineline Cube May 22, 2026
Company Deals

Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform

Fineline Cube May 22, 2026
Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma

Fineline Cube May 24, 2026
Company Drug

Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer

Fineline Cube May 24, 2026
Company Drug

Luye Pharma’s LY03015 Receives FDA Approval for Phase I Clinical Study

Fineline Cube Sep 14, 2022

China-based Luye Pharma Group (HKG: 2186) announced that it has received approval from the US...

Company Deals

Hengrui Medicine to Incentivize Employees with Share Distribution

Fineline Cube Sep 14, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced plans to incentivize its employees...

Policy / Regulatory

Biden’s Executive Order Boosts US Bio-Economy, Targets China’s Biotech Rise

Fineline Cube Sep 13, 2022

US President Joe Biden signed an executive order on Monday, outlining steps to bolster the...

Company Deals

QuantuMDx and Sansure Biotech Partner to Commercialize Q-POC in China

Fineline Cube Sep 13, 2022

UK-based QuantuMDx Group Ltd announced a global R&D, manufacturing, and commercial partnership with China’s Sansure...

Company Drug

InnoCare Pharma’s BCL2 Inhibitor ICP-248 Gains NMPA Approval for Clinical Study

Fineline Cube Sep 13, 2022

China’s Beijing InnoCare Pharma (HKG: 9969) announced that it has received approval from the National...

Company Drug

BeiGene’s Tislelizumab Meets Primary Endpoint in HCC Study at ESMO

Fineline Cube Sep 13, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) presented the latest results of the global Phase...

Company Drug

Luye Pharma’s BA-CovMab Receives NMPA Approval for COVID-19 Clinical Trials

Fineline Cube Sep 13, 2022

China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s...

Policy / Regulatory

Jiangsu Healthcare to Cover All Psychological Treatments Under BMI

Fineline Cube Sep 13, 2022

The Jiangsu Provincial Healthcare Security Administration is reportedly considering adding all psychological diagnosis and treatment...

Company Deals

Leadinno Medical Valley Raises RMB 100M in Series A Financing for Neuromodulation Devices

Fineline Cube Sep 13, 2022

Beijing-based neuromodulation medical device maker Leadinno Medical Valley reportedly raised over RMB 100 million (USD...

Company Drug

Transcenta’s TST001 Shows Promise in Gastric Cancer Trial with 73.3% Response Rate

Fineline Cube Sep 13, 2022

China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced interim safety and efficacy data from a...

Company Drug

CSPC Pharmaceutical’s TG103 Gains NMPA Approval for NASH and Alzheimer’s Trials

Fineline Cube Sep 13, 2022

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...

Company Drug

Jingxin Pharmaceutical Receives NMPA Approval for JBPOS0101 and JX7002 Trials

Fineline Cube Sep 13, 2022

Jingxin Pharmaceutical Co., Ltd (SHE: 002020) announced that it has received clinical trial approvals from...

Drug

China’s Retail Pharmacy O2O Sales Surge to USD 2.9B in 2021

Fineline Cube Sep 9, 2022

According to the “China Retail Pharmacy O2O Development Report” released by Minenet, the “online drug...

Medical Device Policy / Regulatory

National High-Value Medical Consumables VBP Round Targets Orthopedic Spine Products

Fineline Cube Sep 9, 2022

The national high-value medical consumables joint procurement office released a set of guiding opinions on...

Company Drug

China’s Cecolin HPV Vaccine Shows 100% Efficacy in 66-Month Study

Fineline Cube Sep 9, 2022

Chinese researchers have published 66-month follow-up data from a Phase III clinical study for the...

Company Drug

Dizal Pharma’s Sunvozertinib Gains NMPA Approval for EGFR Mutation NSCLC Trial

Fineline Cube Sep 9, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that it has received clinical trial approval...

Company Policy / Regulatory

MofCOM’s 2021 Pharma Distribution Report Shows Market Recovery

Fineline Cube Sep 9, 2022

The Ministry of Commerce (MofCOM) released its annual statistical review of the pharma distribution industry...

Policy / Regulatory

NHSA Issues Notice on Special Treatment of Oral Implant Medical Service Charges

Fineline Cube Sep 9, 2022

The National Healthcare Security Administration (NHSA) has released a Notice on “Carrying out Special Treatment...

Company Drug

Keymed and Lepu’s CMG901 Receives Breakthrough Therapy Designation for Gastric Cancer

Fineline Cube Sep 9, 2022

The Center for Drug Evaluation (CDE) website indicates that CMG901, a Claudin 18.2 (CLDN18.2)-targeted antibody...

Company Deals Digital

Realcan Pharma and AWS Expand Partnership for Digital Transformation

Fineline Cube Sep 9, 2022

China-based Realcan Pharmaceutical Group Co., Ltd (SHE: 002589) and Amazon Web Services (AWS) have agreed...

Posts pagination

1 … 630 631 632 … 670

Recent updates

  • Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma
  • Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer
  • Shanghai Henlius Biotech Secures NMPA Approval for Phase I Trial of HLX48 Bispecific ADC in Advanced Solid Tumors
  • Sino Biopharmaceutical Presents Positive Phase III and II Data for M701 Bispecific Antibody at ASCO 2026
  • Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2/QX001S in Crohn’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma

Company Drug

Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer

Company Drug

Shanghai Henlius Biotech Secures NMPA Approval for Phase I Trial of HLX48 Bispecific ADC in Advanced Solid Tumors

Company Drug

Sino Biopharmaceutical Presents Positive Phase III and II Data for M701 Bispecific Antibody at ASCO 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.